REVIEW ARTICLE THERAPEUTIC PROGRESS–REVIEW XXXVI: ARE WE MAKING PROGRESS IN THE DRUG TREATMENT OF DISORDERS OF THE BLADDER, PROSTATE, and PENIS?

Journal of Clinical Pharmacy and Therapeutics

Volumn 15, Issue 1, 1990, Pages 1-12

  Ryan, P G ^a   Wallace, D M A ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLADDER DISEASE; HUMAN; MALE; PENIS DISEASE; PROSTATE DISEASE; REVIEW; UROLOGY; DRUG THERAPY;

BLADDER DISEASES; HUMAN; MALE; PENILE DISEASES; PROSTATIC DISEASES; UROLOGY;

DESMOPRESSIN; DIMETHYL SULFOXIDE; INDORAMIN; METARAMINOL; NORADRENALIN; OXYBUTYNIN; PAPAVERINE; PENTOSAN POLYSULFATE; PHENTOLAMINE; PRAZOSIN; PROSTAGLANDIN E1; PSEUDOEPHEDRINE; TERODILINE;

EID: 0025330823     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.1990.tb00349.x     Document Type: Review

References (63)

1. Interstitial cystitis. Clinical aspects and treatment
2. Pathology of urinary tract infections
3. Interstitial cystitis
4. The treatment of patients with interstitial cystitis with special reference to intravesical DMSO
5. The use of dimethyl sulfoxide in the treatment of interstitial cystitis
6. Prospective study of intravesical dimethyl sulfoxide in treatment of suspected early interstitial cystitis
7. Prospective study of intravesical dimethyl sulphoxide in the treatment of chronic inflammatory bowel disease
8. Successful treatment of interstitial cystitis with sodium pentosanpolysulfate
9. Treatment of ulcer and nonulcer interstitial cystitis with sodium pentosanpolysulfate: a multicenter trial
10. Successful therapy of interstitial cystitis with pentosanpolysulfate
11. A prospective double‐blind clinically controlled mutlicenter trial of sodium pentosanpolysulfate in the treatment of interstitial cystitis and related painful bladder disease
12. Interstitial cystitis
13. Detrusor instability
14. Pathophysiology of idiopathic detrusor instability and detrusor hyper‐reflexia. An in vitro study of human detrusor muscle
15. Vasoactive intestinal polypeptide in the normal and unstable bladder
16. Oxybutynin hydrochloride: pharmacokinetics and clinical results in the elderly female patient with dextrusor instability
17. The urodynamic and subjective results of treatment of detrusor instability with oxybutynin chloride
18. Oxybutynin chloride in the management of idiopathic dextrusor instability
19. Oxybutynin: is it safe?
20. Anticholinergic and calcium antagonist effects of terodiline in rabbit urinary bladder
21. Effects of nifedipine on smooth muscle of the human urinary tract in vitro and in vivo
22. Effects of nifedipine in women with unstable bladder
23. Terodiline in the treatment of women with urgency and motor urge incontinence. A clinical and urodynamic double‐blind cross‐over study
24. A dose‐related multi‐centre study of terodiline in the treatment of dextrusor instability
25. Terodiline, emepronium bromide or placebo for treatment of female detrusor overactivity? A randomised, double‐blind, cross‐over study
26. Treatment of women with motor urge incontinence with terodiline–a drug with combined anticholinergic and calcium blocking effects
27. Terodiline in the treatment of children with unstable bladders
28. An historical account of enuresis
29. Enuresis and spontaneous cure rate. Study of 1129 enuretics
30. Enuresis
31. Enuresis and the electric alarm. Study of 200 cases
32. Relative nocturnal polyuria as a factor in enuresis
33. Urinary levels of antidiuretic hormone in nocturnal enuresis
34. Diurnal antidiuretic hormone levels in enuretics
35. Diurnal variation in plasma levels of antidiuretic hormone and urinary output in patients with enuresis and control subjects
36. Management of nocturnal enuresis with a vasopressin analogue
37. Assessment of the safety of DDAVP therapy in primary nocturnal enuresis
38. Benign prostatic hypertrophy
39. Structure of the bladder and urethra
40. Bladder outflow obstruction treated with phenoxybenzamine
41. Phenoxybenzamine for the symptoms of bladder neck obstruction
42. The effect of prazosin in benign prostatic hypertrophy, a placebo controlled double blind study
43. Prazosin in the treatment of prostatic obstruction. A placebo‐controlled study
44. Prazosin, priapism and management
45. Indoramin–an effective new drug in the management of bladder outflow obstruction
46. Low dose indoramin, an alpha‐adrenergic antagonist, in the management of benign prostatic hypertrophy
47. Blood flow measurement by the clearance method in the human corpus cavernosum in the flaccid and erect states
48. Cavernosal alpha‐blockade: a new technique for investigating and treating erectile impotence
49. Vipergic nerves in the penis
50. Vasoactive intestinal polypeptide release during penile erection in man
51. Assessment of the immediate and long term effects of pharmacologically induced penile erections in the treatment of psychogenic and organic impotence
52. Diagnostic intracorporeal papaverine and erectile dysfunction
53. Effect of phentolamine on venous return in human erection
54. Impotence: treatment by autoinjection of vasoactive drugs
55. Preliminary report of a new concept in the pharmacological treatment of erectile impotence using an implantable drug delivery system
56. Intracavernous drug‐induced erections in the management of male erectile dysfunction: experience with 100 patients
57. Prostaglandins
58. Contraction and relaxation induced by some prostanoids in isolated human penile erectile tissue and cavernous artery
59. Efficiency and side effects of prostaglandin E1 in the treatment of erectile dysfunction
60. New treatment for priapism
61. Prolonged erections following intracorporeal injection of medications to overcome impotence
62. Editorial comment